Mark A. Graham

Employment

• AstraZeneca UK Limited Associate Director
  2001 - Present

Education

• University of Leeds PhD
  1997 - 2000
• University of Leeds BSc (First Class Honours)
  1994 - 1997

Projects & Funding

Projects & funding information is unavailable.

Publications (36)

• Direct α-C−H Heteroarylation of Unprotected Primary Amines
  ACS Catalysis 2026 DOI: 10.1021/acscatal.6c01036
  +Save
• Direct α-C–H Heteroarylation of Unprotected Primary Amines
  2025 DOI: 10.26434/chemrxiv-2025-q5jr2
  +Save
• Modular Synthesis of Cyclic β-Difluoroamines
  2024 DOI: 10.26434/chemrxiv-2024-fv9g5
  +Save
• Modular synthesis of cyclic β-difluoroamines
  Chemical Communications 2024 DOI: 10.1039/D4CC00640B
  +Save
• Synthesis of Ceralasertib
  Synfacts 2021 DOI: 10.1055/s-0040-1720323
  +Save
• Development and Proof of Concept for a Large-Scale Photoredox Additive-Free Minisci Reaction
  Organic Process Research & Development 2020 DOI: 10.1021/acs.oprd.0c00483
  +Save
• Development and Scale-Up of an Improved Manufacturing Route to the ATR Inhibitor Ceralasertib
  Organic Process Research & Development 2020 DOI: 10.1021/acs.oprd.0c00482
  +Save
• Processes and intermediates for the preparation of a nonracemic sulfimidoylpyrimidinyl pyrrolopyridine
  2020
  +Save
• 10.4 Product Class 4: Benzo[b]thiophenes
  Knowledge Updates 2020/2 2020 DOI: 10.1055/sos-sd-110-01749
  +Save
• Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC)
  Journal of Medicinal Chemistry 2019 DOI: 10.1021/acs.jmedchem.9b01295
  +Save